Effect of high-dose N-acetylcysteine on airway geometry, inflammation, and oxidative stress in COPD patients

International Journal of COPD

Volumn 8, Issue , 2013, Pages 569-579

  De Backer, Jan ^a   Vos, Wim ^a   Van Holsbeke, Cedric ^a   Vinchurkar, Samir ^a   Claes, Rita ^b   Parizel, Paul M ^b   De Backer, Wilfried ^b  

^a FLUIDDA NV   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Chronic obstructive pulmonary disease; Computational fluid dynamics; Computed tomography; Functional respiratory imaging; N acetylcysteine

Indexed keywords

ACETYLCYSTEINE; BUDESONIDE; FORMOTEROL; GLUTATHIONE; GLUTATHIONE PEROXIDASE; INTERLEUKIN 8; PLACEBO;

ADULT; AGED; AIRWAY RESISTANCE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COMPUTATIONAL FLUID DYNAMICS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DRUG EFFECT; DRUG MEGADOSE; DYSPNEA; FEMALE; FUNCTIONAL RESIDUAL CAPACITY; HUMAN; HYPERINFLATION; INFLAMMATION; IONIZING RADIATION; LUNG FUNCTION TEST; MALE; MEASUREMENT REPEATABILITY; OXIDATIVE STRESS; PEAK EXPIRATORY FLOW; PROTEIN BLOOD LEVEL; RADIATION DOSE; RADIATION DOSE REDUCTION; RANDOMIZED CONTROLLED TRIAL; SPUTUM LEVEL; SYMPTOM; TOTAL LUNG CAPACITY;

CHRONIC OBSTRUCTIVE PULMONARY DISEASE; COMPUTATIONAL FLUID DYNAMICS; COMPUTED TOMOGRAPHY; FUNCTIONAL RESPIRATORY IMAGING; N-ACETYLCYSTEINE;

ACETYLCYSTEINE; AGED; AIRWAY RESISTANCE; ANTIOXIDANTS; COMPUTER SIMULATION; CROSS-OVER STUDIES; FEMALE; FORCED EXPIRATORY VOLUME; FUNCTIONAL RESIDUAL CAPACITY; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HUMANS; LUNG; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MULTIDETECTOR COMPUTED TOMOGRAPHY; OXIDATIVE STRESS; PHENOTYPE; PILOT PROJECTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84888172067     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S49307     Document Type: Article

References (25)

1. Hogg JC. Chronic obstructive pulmonary disease: an overview of pathology and pathogenesis. Novartis Found Symp. 2001;234:4-19.
2. Kuwano K, Bosken CH, Paré PD, Bai TR, Wiggs BR, Hogg JC. Small airways dimensions in asthma and in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1993;148(5):1220-1225.
3. Bosken CH, Wiggs BR, Paré PD, Hogg JC. Small airway dimensions in smokers with obstruction to airflow. Am Rev Respir Dis.1990;142(3): 563-570.
4. Sadowska AM, Van Overveld FJ, Górecka D, et al. The interrelationship between markers of inflammation and oxidative stress in chronic obstructive pulmonary disease: modulation by inhaled steroids and antioxidant. Respir Med. 2005;99(2):241-249.
5. Sadowska AM, Verbraecken J, Darquennes K, De Backer WA. Role of N-acetylcysteine in the management of COPD. Int J Chron Obstruct Pulmon Dis. 2006;1(4):425-434.
6. Sadowska AM, Manuel-y-Keenoy B, Vertongen T, et al. Effect of N-acetylcysteine on neutrophil activation markers in healthy volunteers: in vivo and in vitro study. Pharmacol Res. 2006;53(3):216-225.
7. Sadowska AM, Luyten C, Vints A-M, Verbraecken J, Van Ranst D, De Backer WA. Systemic antioxidant defences during acute exacerbation of chronic obstructive pulmonary disease. Respirology. 2006;11(6): 741-747.
8. Decramer M, Rutten-van Mölken M, Dekhuijzen PNR, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet. 2005;365(9470):1552-1560.
9. Sadowska AM, Manuel-Y-Keenoy B, De Backer WA. Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo dose-effects: a review. Pulm Pharmacol Ther. 2007;20(1):9-22.
10. De Backer LA, Vos W, De Backer J, Van Holsbeke C, Vinchurkar S, De Backer W. The acute effect of budesonide/formoterol in COPD: a multi-slice computed tomography and lung function study. Eur Respir J. 2012;40(2):298-305.
11. De Backer JW, Vos WG, Gorlé CD, et al. Flow analyses in the lower airways: patient-specific model and boundary conditions. Med Eng Phys. 2008;30(7):872-879.
12. Vinchurkar S, Backer LD, Vos W, Holsbeke CV, Backer JD, Backer WD. A case series on lung deposition analysis of inhaled medication using functional imaging based computational fluid dynamics in asthmatic patients: effect of upper airway morphology and comparison with in vivo data. Inhal Toxicol. 2012;24(2):81-88.
13. De Backer JW, Vos WG, Vinchurkar SC, et al. Validation of computational fluid dynamics in CT-based airway models with SPECT/CT. Radiology. 2010;257(3):854-862.
14. De Rochefort L, Vial L, Fodil R, et al. In vitro validation of computational fluid dynamic simulation in human proximal airways with hyperpolarized 3He magnetic resonance phase-contrast velocimetry. J Appl Physiol. 2007;102(5):2012-2023.
15. De Backer JW, Vos WG, Devolder A, et al. Computational fluid dynamics can detect changes in airway resistance in asthmatics after acute bronchodilation. J Biomech. 2008;41(1):106-113.
16. De Backer L, Vos W, Salgado R, et al. Functional imaging using computer methods to compare the effect of salbutamol and ipratropium bromide in patient-specific airway models of COPD. Int J Chron Obstruct Pulmon Dis. 2011;2011:6:637-646.
17. Lappas M, Permezel M, Rice GE. N-Acetyl-cysteine inhibits phospholipid metabolism, proinflammatory cytokine release, protease activity, and nuclear factor-kappaB deoxyribonucleic acid-binding activity in human fetal membranes in vitro. J Clin Endocrinol Metabol. 2003;88(4):1723-1729.
18. Ungheri D, Pisani C, Sanson G, et al. Protective effect of n-acetylcysteine in a model of influenza infection in mice. Int J Immunopathol Pharmacol. 2000;13(3):123-128.
19. Cai S, Chen P, Zhang C, Chen J-B, Wu J. Oral N-acetylcysteine attenuates pulmonary emphysema and alveolar septal cell apoptosis in smoking-induced COPD in rats. Respirology. 2009;14(3):354-359.
20. Dekhuijzen PN, Van Beurden WJ. The role for N-acetylcysteine in the management of COPD. Int J Chron Obstruct Pulmon Dis. 2006;1(2):99-106.
21. Stav D, Raz M. Effect of N-acetylcysteine on air trapping in COPD: a randomized placebo-controlled study. Chest. 2009;136(2):381-386.
22. Celli B. COPD, inflammation and its modulation by phosphodiesterase 4 inhibitors: time to look beyond the FEV1. Chest. 2006;129(1):5-6.
23. Jones PW. Health status measurement in chronic obstructive pulmonary disease. Thorax. 2001;56(11):880-887.
24. Wedzicha J, Decramer M, Seemungal T. The role of bronchodilator treatment in the prevention of exacerbations of COPD. Eur Respir J. 2012;40(6):1545-1554.
25. Come CE, Divo MJ, San José Estépar R, et al. Lung deflation and oxygen pulse in COPD: results from the NETT randomized trial. Respir Med. 2012;106(1):109-119.